ArticleAntimicrobial agents and chemotherapy2012
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis.Cellular & molecular immunology · 2021Article
- One Size Fits All? Not inFrontiers in cellular and infection microbiology · 2021Review
- In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment?Nanomaterials (Basel, Switzerland) · 2020Article
- Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.Frontiers in immunology · 2020Article
- Animal models of tuberculosis: Lesson learnt.The Indian journal of medical research · 2018Review
- Delamanid Kills Dormant MycobacteriaAntimicrobial agents and chemotherapy · 2017Article
- Preclinical Efficacy Testing of New Drug Candidates.Microbiology spectrum · 2017Review
- Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen.ACS infectious diseases · 2016Article
- Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?Frontiers in microbiology · 2015Article
- Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.Antimicrobial agents and chemotherapy · 2014Article
- Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.Antimicrobial agents and chemotherapy · 2014Article
- A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.Pharmaceutical research · 2014Article
- A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.Bioorganic & medicinal chemistry letters · 2013Review
- Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.Antimicrobial agents and chemotherapy · 2013Article
- Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis.The Journal of antimicrobial chemotherapy · 2013Article
- Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.Antimicrobial agents and chemotherapy · 2013Article
- Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.Antimicrobial agents and chemotherapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Rifamycins are key sterilizing drugs in the current treatment of active tuberculosis (TB). Daily dosing of rifapentine (P), a potent rifamycin with high intracellular accumulation, in place of rifampin (R) in the standard antitubercular regimen significantly shortens the duration of treatment needed to prevent relapse in a murine model of active TB. We undertook the current study to compare directly the activities of human-equivalent doses of P and R in a guinea pig model of chronic TB, in which bacilli are predominantly extracellular within human-like necrotic granulomas. Hartley strain guinea pigs were aerosol infected with ~200 bacilli of Mycobacterium tuberculosis H37Rv, and treatment given 5 days/week was initiated 6 weeks later. R at 100 mg/kg of body weight and P at 100 mg/kg were given orally alone or in combination with isoniazid (H) at 60 mg/kg and pyrazinamide (Z) at 300 mg/kg. Culture-positive relapse was assessed in subgroups of guinea pigs after completion of 1 and 2 months of treatment. Human-equivalent doses of R and P showed equivalent bactericidal activity when used alone and in combination therapy. In guinea pigs treated with rifampin, isoniazid, and pyrazinamide (RHZ) or PHZ, microbiological relapse occurred in the lungs of 8/10 animals treated for 1 month and in 0/10 animals treated for 2 months. Substitution of P for R in the standard antitubercular regimen did not shorten the time to cure in this guinea pig model of chronic TB. Data from ongoing clinical trials comparing the activity of these two drugs are awaited to determine the relevance of the guinea pig TB model in preclinical drug screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.